Enhancement of volatile fatty acids production through anaerobic co-digestion of navel orange residue and waste activated sludge: Effect of pre-treatment and substrate proportions.

In this study, the co-digestion system with Navel orange residues (NOR) and Waste activated sludge (WAS) was established, by pre-treating the NOR and setting different volatile solids (VS) ratios of NOR to WAS to motivate the production of volatile fatty acids (VFA). The pre-treatment method (pH 7 and temperature 70 °C) promoted the release of dissolved organic matter, and the concentration of soluble chemical oxygen demand (SCOD) increased by 45.56% compared with the untreated group (pH 3 and temperature 20 °C). In the co-digestion system, the highest VFA yield (5716.69 mg/L) was obtained at VS ratio of 2. When the VS ratio was increased to 4, the imbalance in proportions of carbon and nitrogen affected VFA production, and the high concentration of essential oils (EO) present in the NOR inhibited the methane production; the cumulative yield of methane gas decreased by 24.10% compared with the yield obtained when the VS ratio was 2. Analysis of microbial community revealed that an increase in the number of VFA-producing microbial populations and the abundance of Methanobacteria resulted in the accumulation of acetic acid. This study demonstrated that co-digestion of NOR with WAS improve VFA production, thus realizing the utilization of solid wastes and reducing environmental pollution.

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

C3 glomerulopathy (C3G) is a rare renal disease characterized by predominant glomerular C3 staining. Complement alternative pathway dysregulation due to inherited complement defects is associated with C3G. To identify novel C3G-related genes, we screened 86 genes in the complement, coagulation and endothelial systems in 35 C3G patients by targeted genomic enrichment and massively parallel sequencing. Surprisingly, the most frequently mutated gene was VWF. Patients with VWF variants had significantly higher proteinuria levels, higher crescent formation and lower factor H (FH) levels. We further selected two VWF variants to transiently express the von Willebrand factor (vWF) protein, we found that vWF expression from the c.1519A > G variant was significantly reduced. In vitro results further indicated that vWF could regulate complement activation, as it could bind to FH and C3b, act as a cofactor for factor I-mediated cleavage of C3b. Thus, we speculated that vWF might be involved in the pathogenesis of C3G.

[Non-angiogenic functions of vascular endothelial growth factor].

Vascular endothelial growth factor (VEGF or VEGF-A), also named as vascular permeable factor (VPF), is a multi-functional bio-macromolecule belonging to the family of secreted glycoprotein growth factor. VEGF can induce a variety of cellular responses through two high-affinity tyrosine kinases, VEGFR1 and VEGFR2. VEGF plays a key role in the angiogenesis and development in the embryo phase, promoting the proliferation, migration, tube formation and survival of the vascular endothelial cells. In the adult phase, VEGF mainly participates in maintaining the vascular structure and regulating physiological and pathological angiogenesis. Clinical data showed that VEGF signaling inhibitors significantly induced the degeneration of the tumor vessels and reduced tumor size. Meanwhile, various side-effects also have been observed in some patients, indicating that the non-angiogenesis functions of VEGF should be greatly emphasized, especially when developing anti-cancer drugs. Several studies showed that VEGF plays essential roles in various adult organs, such as small intestine, pancreatic islets, thyroid, kidney and liver. When VEGF level in these organs is lower than normal, the complexity of capillary network will be partially degenerated. Apart from that, VEGF also promotes the bone marrow formation, tissue repair and regeneration, the maturation of ovarian, and participates in some pathological courses such as thrombosis, inflammation and ischemia. This review focuses on the non-angiogenesis functions of VEGF and briefly discusses the molecular mechanisms.

CD22 is a functional ligand for SH2 domain-containing protein-tyrosine phosphatase-1 in primary T cells.

The intracellular Src homology 2 (SH2) domain-containing protein-tyrosine phosphatase (SHP-1) has been characterized as a negative regulator of T cell function, contributing to the definition of T cell receptor signaling thresholds in developing and peripheral mouse T lymphocytes. The activation of SHP-1 is achieved through the engagement of its tandem SH2 domains by tyrosine-phosphorylated proteins; however, the identity of the activating ligand(s) for SHP-1, within mouse primary T cells, is presently unresolved. The identification of SHP-1 ligand(s) in primary T cells would provide crucial insight into the molecular mechanisms by which SHP-1 contributes to in vivo thresholds for T cell activation. Here we present a combination of biochemical and yeast genetic analyses indicating CD22 to be a T cell ligand for the SHP-1 SH2 domains. Based on these observations we have confirmed that CD22 is indeed expressed on mouse primary T cells and capable of associating with SHP-1. Significantly, CD22-deficient T cells demonstrate enhanced proliferation in response to anti-CD3 or allogeneic stimulation. Furthermore, the co-engagement of CD3 and CD22 results in a raising of TCR signaling thresholds hence demonstrating a previously unsuspected functional role for CD22 in primary T cells.